Brief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
05/10/2026 12:48
BRIEF-Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology Oct 5 (Reuters) - TuHURA Biosciences Inc HURA.O:
TUHURA BIOSCIENCES RECEIVES KEY U.S. PATENT FOR ITS GROUNDBREAKING DELTA OPIOID RECEPTOR (DOR) ANTIBODY DRUG CONJUGATE (ADC) TECHNOLOGY
Source text: ID:nPn1qcyBYa
Further company coverage: HURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.